Literature DB >> 21426071

Targeting protein-protein interactions for therapeutic intervention: a challenge for the future.

Giovanna Zinzalla1, David E Thurston.   

Abstract

BACKGROUND: Over the last two decades, an increasing research effort in academia and industry has focused on the modulation (both inhibition and stabilization) of protein-protein interactions (PPIs) in order to develop novel therapeutic approaches and target-selective agents in drug discovery. DISCUSSION: The diversity and complexity of highly dynamic systems such as PPIs present many challenges for the identification of drug-like molecules with the ability to modulate the PPI with the necessary selectivity and potency. In this review, a number of these strategies will be presented along with a critical overview of the challenges and potential solutions relating to the exploitation of PPIs as molecular targets.
CONCLUSIONS: Both traditional drug discovery approaches and some more recently developed innovative strategies have already provided valuable tools for the discovery of PPI modulators, and a number of successful examples have highlighted the potential of targeting PPIs for therapeutic intervention, especially in the oncology area.

Mesh:

Substances:

Year:  2009        PMID: 21426071     DOI: 10.4155/fmc.09.12

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  67 in total

Review 1.  Diversity in genetic in vivo methods for protein-protein interaction studies: from the yeast two-hybrid system to the mammalian split-luciferase system.

Authors:  Bram Stynen; Hélène Tournu; Jan Tavernier; Patrick Van Dijck
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

Review 3.  Modulation of nociceptive ion channels and receptors via protein-protein interactions: implications for pain relief.

Authors:  Tom Rouwette; Luca Avenali; Julia Sondermann; Pratibha Narayanan; David Gomez-Varela; Manuela Schmidt
Journal:  Channels (Austin)       Date:  2015-06-03       Impact factor: 2.581

Review 4.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

5.  Elucidating the druggable interface of protein-protein interactions using fragment docking and coevolutionary analysis.

Authors:  Fang Bai; Faruck Morcos; Ryan R Cheng; Hualiang Jiang; José N Onuchic
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-29       Impact factor: 11.205

6.  Investigating cyclic peptides inhibiting CD2-CD58 interactions through molecular dynamics and molecular docking methods.

Authors:  Laurence Leherte; Axel Petit; Denis Jacquemin; Daniel P Vercauteren; Adèle D Laurent
Journal:  J Comput Aided Mol Des       Date:  2018-10-28       Impact factor: 3.686

7.  Enzyme inhibition by allosteric capture of an inactive conformation.

Authors:  Gregory M Lee; Tina Shahian; Aida Baharuddin; Jonathan E Gable; Charles S Craik
Journal:  J Mol Biol       Date:  2011-06-22       Impact factor: 5.469

8.  A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties.

Authors:  Wangxiao He; Jin Yan; Lijuan Wang; Bo Lei; Peng Hou; Wuyuan Lu; Peter X Ma
Journal:  Biomaterials       Date:  2019-03-21       Impact factor: 12.479

9.  Exploring key orientations at protein-protein interfaces with small molecule probes.

Authors:  Eunhwa Ko; Arjun Raghuraman; Lisa M Perez; Thomas R Ioerger; Kevin Burgess
Journal:  J Am Chem Soc       Date:  2012-12-27       Impact factor: 15.419

10.  Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.

Authors:  Mao-Rong Zhu; Dao-Hai Du; Jun-Chi Hu; Lian-Chun Li; Jing-Qiu Liu; Hong Ding; Xiang-Qian Kong; Hua-Liang Jiang; Kai-Xian Chen; Cheng Luo
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.